siRNA / miRNA gene silencing Human PC3 (human prostate cancer cell line)

Get tips on using siRNA PIN1 to perform siRNA / miRNA gene silencing Human - DU145 PIN1

Get tips on using siRNA MXD3 to perform siRNA / miRNA gene silencing Human - DAOY MXD3

Get tips on using siRNA FOXS1 to perform siRNA / miRNA gene silencing Human - DAOY FOXS1

Get tips on using siRNA CBP to perform siRNA / miRNA gene silencing Human - BOSC23 CBP

Get tips on using siRNA ADAM17 to perform siRNA / miRNA gene silencing Human - BOSC23 ADAM17

Get tips on using siRNA AURKA to perform siRNA / miRNA gene silencing Human - A549 AURKA

Get tips on using siRNA EGFR to perform siRNA / miRNA gene silencing Human - A431 EGFR

Get tips on using Control siRNA-A to perform siRNA / miRNA gene silencing Human - OV2008 Yap Gene Lipofectamine

Get tips on using YAP siRNA (h) to perform siRNA / miRNA gene silencing Human - OV2008 Yap Gene Lipofectamine

Short hairpin or small hairpin RNA (shRNA) is artificial RNA, which has a hairpin loop structure, and uses inherent microRNA (miRNA) machinery to silence target gene expression. This is called RNA interference (RNAi). These can be delivered via plasmids or viral/bacterial vectors. Challenges in shRNA-mediated gene silencing include: 1. Off-target silencing, 2. Packaging shRNA encoding lentivirus, and 3. Stable transduction in cells. RNAi have been designed to have anywhere from 19-27 bs, but the most effective design has 19 bp. In case commercial shRNAs are not available, potential target sites can be chosen within exon, 5’- or 3’ UTR, depending on which splice variants of the gene are desired. One should use the latest algorithms and choose at least two different sequences, targeting different regions, in order to have confidence in overcoming off-target effects. A BLAST search after selecting potential design will eliminate potential off-target sequences. For the second challenge, sequencing the vector using primers for either strand (50-100 bp upstream) is suggested, along with using enzymatic digestion on agarose gel for the vector. Next, once the shRNA-containing vector is packaged in a virus, it is important to check the viral titer before transduction. Finally, using a marker in the lentiviral vector (fluorescent protein or antibiotic resistance), along with qPCR for target gene expression can help in determining efficacy of transduction and shRNA on its target site.